Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Decreases By 46.4%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large decline in short interest in July. As of July 15th, there was short interest totalling 144,000 shares, a decline of 46.4% from the June 30th total of 268,800 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.6% of the company’s shares are short sold.

Hedge Funds Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. purchased a new position in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned approximately 0.51% of BioRestorative Therapies as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 69.38% of the company’s stock.

BioRestorative Therapies Price Performance

BioRestorative Therapies stock traded down $0.05 during midday trading on Friday, hitting $1.62. 46,349 shares of the company were exchanged, compared to its average volume of 49,431. The company’s fifty day moving average price is $1.65 and its 200-day moving average price is $1.52. The company has a market cap of $10.97 million, a PE ratio of -0.70 and a beta of 63.43. BioRestorative Therapies has a fifty-two week low of $1.03 and a fifty-two week high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings results on Tuesday, June 11th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative return on equity of 96.09% and a negative net margin of 7,303.33%. On average, analysts expect that BioRestorative Therapies will post -2.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $15.00 price objective on shares of BioRestorative Therapies in a research note on Wednesday, June 12th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.